NCT04398108View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 25, 2020

Primary Completion Date

April 27, 2021

Study Completion Date

April 27, 2021

Conditions
HER2 Positive Metastatic Breast Cancer
Interventions
DRUG

Margetuximab Margetuximab-IV

Drug: Chosen Chemotherapy (Capecitabine) -Oral Capecitabine tablet Drug: Chosen Chemotherapy (Vinorelbine) Vinorelbine -IV Drug: Chosen Chemotherapy (Gemcitabine) Gemcitabine -IV

Trial Locations (3)

100071

The fifth medical center of the General Hospital of people's Liberation Army of China, Beijing

450000

Henan Cancer Hospital, Zhengzhou

050000

The fourth hospital of Hebei Medical University, Shijiazhuang

All Listed Sponsors
lead

Zai Lab (Shanghai) Co., Ltd.

INDUSTRY

NCT04398108 - A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC | Biotech Hunter | Biotech Hunter